Material
U pon antigenic stimulation, naive CD4
+ Th cells differentiate into different subtypes of effector Th cells and then modulate the immune response to intracellular or extracellular pathogens (1) . Th1 and Th2 cells are the two major cell types derived from naive CD4 + T cells (2-4); however, Th17 and induced regulatory T (iTreg) cells have recently been identified as new Th subsets (5-7). These multitasking Th subsets are characterized by the production of signature cytokines: IFN-g (Th1); IL-4, IL-5, and IL-13 (Th2); IL-17 (Th17) cells; and TGF-b and IL-10 (iTreg) (8) . Lineage commitment to the effector Th cells and iTreg cells is determined by the activation of lineage-specific transcription factors in response to extracellular cytokines. TCR triggering immediately activates transcription factors such as NFAT1 and NF-kB, which then directly bind to the IL-2 and Th2 cytokine gene promoters and induce their expression, which is associated with cell proliferation and differentiation (9) (10) (11) . In addition, cytokine stimulation of CD4 + T cells induces activation of master transcription factors that direct lineage-specific cytokine production. For example, IL-12 and IFN-g activate the Th1-specific transcription factor, T-box protein expressed in T cells (T-bet), and they induce differentiation of CD4 + T cells into Th1 effector cells (12) , whereas IL-4 induces activation of Th2-specific GATA-binding protein-3 (GATA-3) for Th2 cell development (13) . TGF-b enhances not only Treg cell development through activation of forkhead protein p3 (Foxp3) (14, 15) but also Th17 differentiation via activation of retinoic acidrelated orphan receptor-g t by coordination with IL-6 (16) .
In particular, a Th1-specific master regulator, T-bet plays multiple roles in the development of all subsets of effector Th and iTreg cells. T-bet is prominently expressed in developing Th1 cells, and enforced T-bet expression directs the development of naive CD4 + T cells into Th1 cells and converts differentiated Th2 cells into Th1 cells (12) . Because T-bet contains a conserved DNA-binding domain called the T-box, it specifically binds to the T-box binding element within the promoter and enhancer region of the IFN-g gene and thus facilitates IFN-g gene transcription (17) . In addition, T-bet suppresses Th2 cell development and IL-2 production via IFN-g-independent mechanisms (18) (19) (20) . T-bet undergoes tyrosine phosphorylation mediated by IL-2-inducible tyrosine kinase, which leads to suppression of GATA-3-induced Th2 cell differentiation (18) . In addition, phosphorylation of T-bet at serine residues is a prerequisite for inhibiting IL-2 production through NF-kB p65 interaction (19) . Furthermore, T-bet inhibits NFAT1 activity through physical interaction, resulting in IL-21 suppression (19, 21) . Recent studies have shown that T-bet negatively controls the development of Th17 cells through inhibition of RUNX1 activity and modulates homeostasis and function of iTreg cells (22, 23) . Despite the critical role of T-bet during Th cell differentiation, the molecular mechanisms underlying the regulation of T-bet protein stability remain unclear. In this study, we investigated whether T-bet expression is controlled by the ubiquitin (ub)-proteasomal degradation pathway. We found that T-bet underwent ubiquitination at Lys-313, which targeted the protein for proteasomal degaradation. Furthermore, Lys-313 was required for T-bet to interact with the IFN-g gene promoter and to induce phosphorylation at Thr-302, thereby suppressing NFAT1 activity.
Materials and Methods

Reagents
All cytokines and Abs against cytokines were purchased from BD Pharmingen (San Jose, CA), eBioscience (San Diego, CA), and R&D Systems (Minneapolis, MN). Flag-M2 agarose, anti-Flag Ab, PMA, and ionomycin were obtained from Sigma-Aldrich (St. Louis, MO). Abs against T-bet (4B10), NFAT1, NFkB p65, hemagglutinin (HA), OCT1, and b-actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and Abs for phospho-serine, and phospho-threonine were from Zymed Laboratories (South San Francisco, CA).
Animals
C57BL/6 wild-type (WT) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). WT and T-bet knockout (KO) mice were housed in specific pathogen-free conditions at Ewha Womans University (Seoul, South Korea). All animal studies were conducted in accordance with Institutional Animal Care and Use Committee (IACUC) guidelines and were approved by the IACUC at Ewha Womans University (IACUC 2011-01-074).
Activation and differentiation of Th cells and retroviral transduction
Single-cell suspensions were obtained from the lymph nodes of WT and Tbet KO mice and incubated with magnetic beads coated with anti-mouse CD4 + Ab, followed by column purification (Miltenyi Biotec, Auburn, CA). Isolated CD4 + T cells (2 3 10 6 cells/ml) were stimulated with platebound anti-CD3 (2 mg/ml) and anti-CD28 (1 mg/ml) Abs in the presence of recombinant human IL-2 (10 U/ml) for 24 h. Cells were then infected by mixing with fresh viral supernatants expressing WT or mutant T-bet for 24 h. After removal of the virus-containing medium, either GFP-sorted or unsorted cells were expanded in RPMI 1640 medium with 10% FBS for an additional 3-5 d and then restimulated with anti-CD3 Ab (1 mg/ml) for 24 h. The viral supernatants were harvested 48 h after transfection with Tbet expression vector into Phoenix cells, followed by concentration using PEG virus precipitation kit (Bio Vision, Mountain View, CA) and addition to the medium of activated Th cells.
Reporter gene assay
EL4 cells were transfected with a reporter gene (pIFN-g-luc, pIL-4-luc, pIL-2-luc, or 23 NFAT-luc) and expression vector (NFAT1, T-bet, or NFkB p65) as well as pCMV-b expressing b-galactosidase (Invitrogen, Carlsbad, CA). pIFN-g-luc, pIL-4-luc, and pIL-2-luc contain ∼500-bp upstream promoter regions of IFN-g, IL-4, and IL-2 genes, respectively, and 23 NFAT-luc is a luciferase gene linked with two copies of the consensus NFAT-binding element (19) . Reporter gene activity was assayed using a luciferase assay kit (Promega, Madison, WI) and galactosidase assay kit Galacto-Light (Tropix, Bedford, MA). At least three independent experiments were conducted.
Reverse transcription and quantitative real-time PCR analysis
Total RNA was prepared using TRIzol reagent (Life Technologies, Invitrogen) followed by reverse transcription with Superscript II (Invitrogen). Real-time PCR was performed using SYBR Green premix buffer (PerkinElmer Applied Biosystems, Foster City, CA) and specific primers. Primers were as follows: IFN-g, 59-AGCAACAGCAAGGCGAAAA-39, 59-CT-GGACCTGTGGGTTGTTGA-39; T-bet, 59-GCCAGGGAACCGCTTA-TATG-39, 59-GACGATCATCTGGGTCACATTGT-39; IL-2, 59-CCTGA-GCAGGATGGAGAATTACA-39, 59-TCCAGAACATGCCGCAGAG-39; IL-4, 59-ACAGGAGAAGGGACGCCAT-39, 59-GAAGCCCTACAGACGAGCTC-A-39; and b-actin, 59-AGAGGGAAATCGTGCGTGAC-39, 59-CAATAGTG-ATGACCTGGCCGT-39. Real-time PCR was performed using an ABI-Prism 7000 sequence detector (Perkin-Elmer Applied Biosystems), and the relative expression level was calculated after normalization to the level of b-actin.
Immunoprecipitation and immunoblotting
293T cells were transfected with either Flag-tagged WT or mutant T-bet expression vectors with or without NFAT1 or NF-kB p65. Whole-cell extracts were harvested 2 d posttransfection and incubated with Flag-M2 agarose beads (Sigma-Aldrich), which were then washed with lysis buffer. Immune complexes or whole-cell extracts were resolved by SDS-PAGE and subjected to immunoblot analysis using Abs against NF-kB p65, and NFAT1 (Santa Cruz Biotechnology).
DNA pull-down assay
Whole-cell extracts were prepared in HKMG buffer (10 mM HEPES [pH 7.9], 100 mM KCl, 5 mM MgCl 2 , 10% glycerol, 0.1% Nonidet P-40, and 1 mM DTT). dsDNA of the T-box binding sequence of the IFN-g promoter was biotinylated and incubated with whole-cell extracts. The protein-DNA-binding complex was precipitated with streptavidin-agarose beads and then subjected to SDS-PAGE and immunoblotting.
Intracellular cytokine staining
For intracellular cytokine staining, cells were pretreated with monensin (4 mM) for 2 h and then harvested. Cells were fixed with 4% paraformaldehyde solution, rinsed with permeabilization buffer (0.1% saponin and 1% FBS in PBS), and incubated with PE-conjugated anti-IFN-g or anti-IL-5 Ab. Cells were then washed twice with FACS buffer (2% FBS in PBS) and analyzed with a FACSCalibur (BD Biosciences, San Jose, CA). Cell populations were measured using CellQuest software (BD Biosciences).
Statistical analysis
The results are given as mean 6 SEM. Statistical significance was determined by one-way ANOVA or two-tailed unpaired Student t test. p , 0.05 was considered statistically significant: *p , 0.05; **p , 0.005; ***p , 0.0005.
Results
T-bet protein undergoes ub-mediated proteasomal degradation
Although T-bet is abundantly expressed under Th1-skewing conditions, the T-bet protein is decreased during late stages of Th1 cell development (18) . To measure T-bet protein stability, we treated developing Th1 cells with cycloheximide (CHX) and examined the expression level of T-bet. T-bet protein was decreased after CHX treatment in a time-dependent manner, displaying a half-life of ∼4 h (Fig. 1A) . T-bet reduction by treatment with CHX was inhibited in the presence of MG132, a proteasome inhibitor (Fig. 1B) . We then performed the in vitro ubiquitination assay of T-bet protein by transfection of T-bet and ub expression vector into 293T cells and found that T-bet was polyubiquitinated (Fig. 1C ). In addition, T-bet was predominantly expressed in the nucleus and also observed in the cytoplasm after treatment with MG132 ( Fig. 1D) , suggesting a stabilized T-bet in the cytoplasm. As all the lysines of T-bet are within the T-box (Tbx) and C-terminal (CT) domain, we constructed T-bet truncations Tbx and CT for in vitro ubiquitination. Interestingly, the T-box, not the CT, domain of T-bet was specifically ubiquitinated by the overexpression of ub (Fig. 1E ).
Lys-313 is important for controlling the T-bet protein stability
We intended to identify the ubiquitination sites within the Tbx by mutation of lysine to arginine or alanine. Among the 11 lysine residues within the Tbx, 3 highly conserved lysine residues (Lys-208, Lys-313, and Lys-321) in the helical DNA-binding motifs were selected (24) and mutated to arginine (Fig. 2A) . The expression levels were comparable between WT and mutants of T-bet, except that T-bet K313R showed a lower shifted band unlike the other mutants, which yielded two shifted bands (Supplemental Fig.  1A ). We first examined the protein stability of T-bet after treatment with CHX. The protein level of WT T-bet, T-bet K208R , and Tbet K321R was decreased by treatment with CHX, whereas T-bet K313R level were unchanged (Fig. 2B ). Subcellular localization of T-bet proteins was then determined using nuclear and cytoplasmic fractions. Although WT T-bet, T-bet K208R , and T-bet K321R were exclusively expressed in the nucleus, T-bet K313R was expressed in both nuclear and cytoplasmic compartments (Fig. 2C) . Fluorescence microscopic observation confirmed that GFP-tagged T-bet K313R was expressed not only in the nucleus but also in the cytoplasm compared with WT T-bet and T-bet K208R (Fig. 2D) . Finally, the in vitro ubiquitination assay verified that T-bet K313R was much less ubiquitinated compared with WT T-bet (Fig. 2E) . Furthermore, we confirmed that Lys residues of T-bet were not modified by either acetylation or sumoylation (Supplemental Fig. 1B, 1C ).
Lys-313 is essential for T-bet binding to the T-box-binding element within the IFN-g promoter
Because Lys-313 mutation resulted in increased T-bet expression, we initially expected that this mutant would exhibit higher transcriptional activity compared with WT. Ectopic overexpression of WT T-bet significantly increased IFN-g promoter activity; however, T-bet K313R was actually impaired in the induction of the promoter activity (Fig. 3A) . We thus compared the DNA-binding activity of WT T-bet and T-bet K313R with a biotinylated DNA pulldown assay. Although WT T-bet strongly bound to the T-boxbinding element of the IFN-g gene promoter, the mutation of Lys-313 abolished the DNA-binding activity of T-bet (Fig. 3B) . We additionally observed that Lys-208 and Lys-321 were not essential for DNA binding because T-bet K208R and T-bet K321R bound to the DNA as efficiently as WT T-bet (Supplemental Fig. 2A ). Most interestingly, the stereo view of the crystal structure of DNA bound T-bet revealed that the positively charged side-chain nitrogen of Lys-313 was associated with the negatively charged phosphate group of one of the DNA bases within the T-box binding elements (Fig. 3C ). Thr-302, which is found in the loop The
Mutation of K313 abolishes T-bet functions in CD4 + T cell development
We investigated whether T-bet requires Lys-313 to induce Th1 cell development or to suppress IL-2 and cytokine production by Th2 cells in vitro. WT T-bet and T-bet K313R were introduced into T-betdeficient CD4 + Th cells by retroviral transduction, and cells were then stimulated to induce differentiation into Th2 cells. Comparable expression of WT T-bet and T-bet K313R in CD4 + Th cells was verified by immunoblotting (Fig. 4A) . WT T-bet expression restored IFN-g production in T-bet-null CD4 + Th cells, whereas enforced expression of T-bet K313R was unable to restore IFN-g production. ELISA and real-time PCR analyses demonstrated that no expression of either IFN-g protein or mRNA was observed upon T-bet K313R restoration (Fig. 4B, 4C ). Intracellular cytokine staining also revealed impaired IFN-g production in T-bet K313R -transduced cells (Fig. 4D) , which was consistent with a loss of DNA-binding activity of T-bet K313R . More strikingly, the suppression activity of WT T-bet in IL-2 and Th2 cytokine production was completely absent in T-bet K313R (Fig. 4E, 4F ), implicating an important role of Lys-313 in suppressing IL-2 and Th2 cytokine production.
Lys-313 is crucial for Thr-302 phosphorylation of T-bet and its interaction with NFAT1
The inability of T-bet K313R to suppress IL-2 and Th2 cytokine production prompted us to investigate the underlying molecular mechanisms. Because T-bet modulates the activity of GATA-3, NF-kB p65, and NFAT1 through a modification-dependent physical interaction (18, 19, 21) , we examined the effect of mutation of Lys-313 on protein-protein interactions. Interestingly, physical association between T-bet and NFAT1 was diminished by Lys-313 mutation (Fig. 5A) , whereas the interaction of T-bet with either NF-kB p65 or GATA-3 was sustained by the mutation (Fig. 5B,  Supplemental Fig. 2B ). Simultaneously, neither tyrosine nor serine phosphorylation was drastically changed in T-bet K313R (Fig. 5C,  Supplemental Fig. 2C ). However, threonine phosphorylation was strikingly abolished in T-bet K313R (Fig. 5C ). To identify threonine phosphorylation sites, we mutated highly conserved threonine residues among species and compared the phosphorylation status and NFAT1 interaction. Threonine phosphorylation and NFAT1 interaction were generally comparable between WT T-bet and most of the threonine mutants of T-bet (Supplemental Fig. 3A, 3B) . However, T-bet T302A substantially decreased both threonine phosphorylation, as evidenced by immunoblotting with an antiphospho-threonine Ab (Fig. 5D ) and the interaction with NFAT1 (Fig. 5E) ; it had no effect on NF-kB p65 interaction (Supplemental Fig. 3C ). We also observed that endogenous T-bet in developing Th1 cells was phosphorylated at threonine residues, but this was less robust than serine or tyrosine phosphorylation (Fig. 5F ).
Thr-302 phosphorylation specifically suppresses NFAT1 transcriptional activity
We then assessed the effect of T-bet T302A on the ability of NFAT1 to induce cytokine gene expression. Although WT T-bet expression suppressed NFAT1-induced IL-2 promoter activity, T-bet T302A had no inhibitory effect on NFAT1 activity similar to the results with T-bet K313R (Fig. 6A ). NFAT1-mediated IL-4 promoter activity was also suppressed by WT T-bet or T-bet T310A but not by T-bet K313R or T-bet T302A (Fig. 6B ). Activity of a 23 NFAT-luc reporter (containing two copies of NFAT1-binding element) was enhanced by + T cells were activated with anti-CD3 (2 mg/ml) and anti-CD28 (1 mg/ml) under Th1-skewing conditions for the indicated time periods. Protein extracts were immunoprecipitated with Tbet Ab, and endogenous T-bet immune complexes were resolved by SDS-PAGE and immunoblotted with pThr, pSer, pTyr, and T-bet Ab. NFAT1 expression; this effect was then decreased by WT T-bet but not by T-bet T302A (Fig. 6C ). This implies that threonine phosphorylated T-bet specifically suppresses NFAT1. We also evaluated the effect of T-bet T302A on IFN-g promoter activity. Surprisingly, IFN-g promoter activity was increased by both WT and T-bet T302A , whereas T-bet K313R had no stimulatory effect (Fig. 6D) . In addition, DNA-pull down assays confirmed that T-bet T302A retained DNA-binding activity on the IFN-g promoter, unlike T-bet K313R (Supplemental Fig. 4A ), which is consistent with the increased IFN-g promoter activity in the presence of T-bet T302A . Moreover, unlike T-bet K313R , T-bet T302A was highly expressed in the nucleus and degraded in the presence of CHX (Supplemental Fig. 4B, 4C ).
Threonine phosphorylation of T-bet is critical for inhibition of NFAT1-mediated IL-2 and Th2 cytokine production Finally, we investigated the importance of threonine phosphorylation in NFAT1-induced cytokine production by CD4 + Th cells. The level of T-bet expression was comparable between WT and T-bet T302A (Fig. 7A ). Viral transduction of T-bet T302A into T-bet-null cells restored IFN-g production to the levels seen in the presence of WT T-bet, but T-bet T302A failed to suppress IL-5 production (Fig. 7B ). Consistently, a comparable level of IFN-g was found in cells expressing both WT T-bet and T-bet T302A , as evidenced by ELISA and real-time PCR (Fig. 7C, 7D ). NFAT1-induced cytokines, IL-2, IL-5, and IL-13 were significantly suppressed by WT T-bet expression, whereas T-bet T302A lost this property (Fig. 7E, 7F) . Furthermore, the relative transcription level of IL-2 and IL-4 was not inhibited by T-bet T302A (Fig. 7G) . These results indicate that threonine phosphorylation is crucial for the suppression of IL-2 and Th2 cytokine production but has no significant effect on DNA binding to the IFN-g promoter and subsequent transactivation.
Discussion
Our results demonstrate that Lys-313 of the Tbx plays crucial roles in T-bet functions. First, Lys-313 controls the stability of T-bet via ubiquitination and proteasomal degradation in the cytoplasm. Second, Lys-313 is involved in direct interaction with the negatively charged phosphate group of nucleotides in the IFN-g gene promoter. Last, Lys-313 is important for interacting with NFAT1 through induction of phosphorylation at Thr-302, thus suppressing NFAT1 activity.
Lys-313 is located in the a-helix 3 region of the Tbx, an evolutionarily conserved DNA-binding domain, comprising 180-200 aa (24) . The Tbx directly binds to a consensus T-box-binding element, 59-TCACACCT-39 within the promoter or enhancer and modulates gene transcription (25, 26) ; thus, many T-box proteins play important roles in organ development (27, 28) , embryogenesis (29, 30) , and cell proliferation (31, 32) . Lys-313 of T-bet corresponds to Lys-228 of TBX2 or Lys-271 of TBX22, which is a SUMOylation site (33) (34) (35) . Our study demonstrates that Lys-313 of T-bet is an ubiquitination site but not a site for SUMOylation or acetylation. T-bet K313R engendered attenuated protein degradation in the presence of CHX, which lead us to expect the enhanced IFN-g production due to the elevation of protein stability. However, our results revealed precisely the opposite: mutation of Lys-313 impairs T-bet's ability to activate IFN-g gene transcription because of the loss of DNA-binding activity. The direct electrostatic interaction between Lys-313 of T-bet and the DNA element is directly supported by the crystal structure of Tbet bound to DNA.
According to our present results, Lys-313 of T-bet is important not only for inducing IFN-g gene transcription but also for sup- pressing IL-2 and Th2 cytokine production. T-bet plays different roles in regulating cytokine expression through different mechanisms. It undergoes tyrosine phosphorylation and specifically associates with a Th2-specific transcription factor, GATA-3, resulting in an IFN-g-independent suppression of Th2 cell development (18) . Moreover, T-bet fine-tunes IL-2 level during Th1 cell differentiation by suppressing NF-kB p65 activity in a serine phosphorylation-dependent manner (19) T-bet K313R associates with both GATA-3 and NF-kB p65 as effectively as WT T-bet, and the mutation does not perturb phosphorylation at tyrosine and serine residues. However, NFAT1 interaction is diminished in Tbet K313R . NFAT1 is a critical transcription factor required for activating many cytokines, including IL-2, IL-4, IL-5, and IL-13. Therefore, loss of interaction with NFAT1 abrogates T-bet's ability to suppress NFAT1-dependent IL-2 and Th2 cytokine expression. Interestingly, T-bet K313R also abrogates T-bet phosphorylation at Thr-302. We first demonstrated that Thr-302 phosphorylation of T-bet is essential for interacting with NFAT1 and suppressing NFAT1-induced cytokine production. Because NFAT1 also increases IL-17 and IL-10 expression (36-38), T-bet may also suppress IL-17 and IL-10 production by inhibiting NFAT1 activity through a phosphorylation-dependent interaction.
T-bet undergoes a variety of posttranslational modifications such as ubiquitination, serine, threonine, and/or tyrosine phosphorylation. It then modulates production of various cytokines through specific interaction with different transcription factors in CD4 + Th cells, resulting in a differential regulation of Th cell development. In particular, Lys-313 of the Tbx is crucial for controlling T-bet protein stability and interacting with DNA. However, it remains to be clarified what percentage of the total amount of T-bet undergoes protein modification, under what physiological circumstances T-bet is modified, and how the choice of T-bet-binding partners is made. It would be very interesting to determine which modification has a priority among various posttranslational modifications of T-bet. Although the mutation of Lys-313 affects protein degradation and Thr-302 phosphorylation of T-bet, mutation of Thr-302 does not affect protein stability. The DNA-binding activity of Thr-302 mutant of T-bet is slightly lower than that of WT, suggesting a mild effect of Thr-302 on DNA binding. This is because Thr-302 is located on the same face of the helix as Lys-313. This suggests that Lys-313 has an essential role in ubiquitination, DNA binding, and induction of Thr-302 phosphorylation. It would also be interesting to see whether the DNA-binding activity of T-bet is required for its protection from the proteasomal degradation or whether Thr-302 phosphorylation affects other modifications at Ser-508 and Tyr-525 residue.
Taken together, our data indicate that Lys-313 of the Tbx of T-bet is a prerequisite for T-bet functions in the control of ub-mediated protein degradation, the direct interaction with phosphate of the Tbox-binding DNA element, and the association with and suppression of NFAT1 through Thr-302 phosphorylation. 
